| pubmed-article:9827984 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C0038250 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C0229664 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C0023484 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C0206152 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C0242596 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C0677874 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C1522577 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C1521991 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C1550594 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C1548760 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C1547300 | lld:lifeskim |
| pubmed-article:9827984 | lifeskim:mentions | umls-concept:C0580822 | lld:lifeskim |
| pubmed-article:9827984 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:9827984 | pubmed:dateCreated | 1999-2-10 | lld:pubmed |
| pubmed-article:9827984 | pubmed:abstractText | Plasma cell leukemia is a rare disease associated with very poor survival with standard treatment. We report a patient affected by plasma cell leukemia treated with aggressive chemotherapy and autologous CD34-selected PBPC who achieved a complete remission now lasting more than 2 years. Molecular studies confirmed the presence of minimal residual disease (MRD) despite the absence of disease activity. High-dose chemotherapy with stem cell rescue may be applied to selected patients considering the impact of the treatment on survival. The meaning of molecular MRD in this setting is unclear. | lld:pubmed |
| pubmed-article:9827984 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9827984 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9827984 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9827984 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9827984 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9827984 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9827984 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:9827984 | pubmed:author | pubmed-author:LeoneGG | lld:pubmed |
| pubmed-article:9827984 | pubmed:author | pubmed-author:SicaSS | lld:pubmed |
| pubmed-article:9827984 | pubmed:author | pubmed-author:SalutariPP | lld:pubmed |
| pubmed-article:9827984 | pubmed:author | pubmed-author:Ortu La... | lld:pubmed |
| pubmed-article:9827984 | pubmed:author | pubmed-author:LaurentiLL | lld:pubmed |
| pubmed-article:9827984 | pubmed:author | pubmed-author:ChiusoloPP | lld:pubmed |
| pubmed-article:9827984 | pubmed:author | pubmed-author:SerraF GFG | lld:pubmed |
| pubmed-article:9827984 | pubmed:author | pubmed-author:PiccirilloNN | lld:pubmed |
| pubmed-article:9827984 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9827984 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:9827984 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9827984 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9827984 | pubmed:pagination | 823-5 | lld:pubmed |
| pubmed-article:9827984 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:9827984 | pubmed:meshHeading | pubmed-meshheading:9827984-... | lld:pubmed |
| pubmed-article:9827984 | pubmed:meshHeading | pubmed-meshheading:9827984-... | lld:pubmed |
| pubmed-article:9827984 | pubmed:meshHeading | pubmed-meshheading:9827984-... | lld:pubmed |
| pubmed-article:9827984 | pubmed:meshHeading | pubmed-meshheading:9827984-... | lld:pubmed |
| pubmed-article:9827984 | pubmed:meshHeading | pubmed-meshheading:9827984-... | lld:pubmed |
| pubmed-article:9827984 | pubmed:meshHeading | pubmed-meshheading:9827984-... | lld:pubmed |
| pubmed-article:9827984 | pubmed:meshHeading | pubmed-meshheading:9827984-... | lld:pubmed |
| pubmed-article:9827984 | pubmed:meshHeading | pubmed-meshheading:9827984-... | lld:pubmed |
| pubmed-article:9827984 | pubmed:meshHeading | pubmed-meshheading:9827984-... | lld:pubmed |
| pubmed-article:9827984 | pubmed:meshHeading | pubmed-meshheading:9827984-... | lld:pubmed |
| pubmed-article:9827984 | pubmed:meshHeading | pubmed-meshheading:9827984-... | lld:pubmed |
| pubmed-article:9827984 | pubmed:meshHeading | pubmed-meshheading:9827984-... | lld:pubmed |
| pubmed-article:9827984 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9827984 | pubmed:articleTitle | Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant: molecular follow-up of minimal residual disease. | lld:pubmed |
| pubmed-article:9827984 | pubmed:affiliation | Istituto di Semeiotica Medica, Divisione di Ematologia, Università Cattolica Sacro Cuore, Roma, Italy. | lld:pubmed |
| pubmed-article:9827984 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9827984 | pubmed:publicationType | Case Reports | lld:pubmed |
| pubmed-article:9827984 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9827984 | lld:pubmed |
